N/A
Manufactured by Aarkish Pharmaceuticals NJ Inc.
29,146 FDA adverse event reports analyzed
Last updated: 2026-04-14
METOLAZONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aarkish Pharmaceuticals NJ Inc.. The most commonly reported adverse reactions for METOLAZONE include DYSPNOEA, DEATH, ACUTE KIDNEY INJURY, NAUSEA, RENAL FAILURE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METOLAZONE.
Out of 10,862 classified reports for METOLAZONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 29,146 FDA FAERS reports that mention METOLAZONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, DEATH, ACUTE KIDNEY INJURY, NAUSEA, RENAL FAILURE, CARDIAC FAILURE CONGESTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aarkish Pharmaceuticals NJ Inc. in connection with METOLAZONE. Always verify the specific product and NDC with your pharmacist.